Skip to main content

Table 2 Clinicopathological characteristics of primary breast cancer patients in BCA cohort and HER2+ BCA cohort

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Characteristic n BCA cohort, n (%) n HER2-amplified BCA cohort, n (%)
Follow-up period for RFS (range)   Mean 10.4 yr. (1 mo.-22 yr.)   Mean 5.3 yr. (1 mo.-9 yr.)
Age (range) 308 Median 61 yr. (32–93 yr.) 177 Median 60 yr. (29–91 yr.)
 < 50 years   64 (20.8)   36 (20.3)
 ≥ 50 years   244 (79.2)   141 (79.7)
HER2 status 308   177  
 Positive   47 (15.3)   177 (100.0)
 Negative   261 (84.7)   0 (0.0)
ER status 307   177  
 Positive (≥10%)   248 (80.8)   113 (63.8)
 Negative (< 10%)   59 (19.2)   64 (36.2)
PR status 307   177  
 Positive (≥10%)   201 (65.5)   74 (41.8)
 Negative (< 10%)   106 (34.5)   103 (58.2)
Triple negativity 307   177  
 TNBC (HER2−/ER-/PR-)   30 (9.8)   0 (0.0)
 No TNBC   277 (90.2)   177 (100.0)
Histological grade 232   174  
 I-II   179 (77.2)   41 (23.6)
 III   53 (22.8)   133 (76.4)
Ki67 proliferation index 230   177  
 Low (< 20%)   165 (71.7)   33 (18.6)
 High (≥20%)   65 (28.3)   144 (81.4)
Histological type 304   168  
 Ductal   173 (56.9)   156 (92.9)
 Lobular   131 (43.1)   12 (7.1)
Tumour size 177   142  
 < 2 cm   57 (32.2)   68 (47.9)
 ≥ 2 cm   120 (67.8)   74 (52.1)
Tumour size 308   172  
 pT1-pT2   282 (91.6)   161 (93.6)
 pT3-pT4   26 (8.4)   11 (6.4)
Lymph nodal spread 286   169  
 Positive pN+   114 (39.9)   73 (43.2)
 Negative pN0   172 (60.1)   96 (56.8)
  1. Number of patient cases with available data (n) for each character is marked within the columns